<DOC>
	<DOCNO>NCT01440192</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single dose PDA001 ( give twice ) subject Stage II III Pulmonary Sarcoidosis ( PS ) refractory one follow treatment PS : methotrexate , immunosuppressant cytotoxic agent .</brief_summary>
	<brief_title>Safety Intravenous Infusion Human Placenta-Derived Cells ( PDA001 ) Treatment Adults With Stage II III Pulmonary Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<criteria>1 . Male female subject 18 year 75 year age time sign informed consent document 2 . Understand voluntarily sign informed consent document prior studyrelated assessments/procedures conduct 3 . Must able adhere study visit schedule protocol requirement 4 . Weight must ≥ 50 kg 5 . A female childbearing potential ( FCBP ) must negative serum urine pregnancy test within 24 hour prior treatment study therapy . In addition , sexually active FCBP must agree use two follow adequate form contraception method simultaneously : oral , injectable implantable hormonal contraception ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomize partner duration study followup period . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity FCBP duration study followup period 6 . Diagnosis sarcoidosis evidence parenchymal disease chest radiograph ( Stage II III ) , well histologic confirmation granulomatous inflammation disease duration ≥ 1 year 7 . Refractory one following ; methotrexate , immunosuppressant cytotoxic agent 8 . Forced vital capacity ( FVC ) ≥ 45 % ≤ 80 % predict normal value screen 9 . Must stable dose prednisone , methotrexate , and/or azathioprine pulmonary Sarcoidosis 4 week prior infusion IP 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 2 . Any condition confound ability interpret data study 3 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 4 . Subjects Stage I Stage IV sarcoidosis 5 . Subjects cutaneous sarcoidosis 6 . Subjects neurosarcoidosis ( clinically apparent ) cardiac sarcoidosis 7 . Lung disease , sarcoid relate , asthma , chronic obstructive pulmonary disease ( COPD ) , interstitial lung disease ( ILD ) 8 . History listeriosis , coccidiomycosis , histoplasmosis , blastomycosis , treat untreated tuberculosis exposure individual tuberculosis 9 . History pulmonary emboli deep vein thrombus 10 . Active smoker previous smoker &gt; 10 pack year ( PY ) . Previous smoker must discontinue smoke least 1 year 11 . Morbidly obese [ Body Mass Index ( BMI ) ] &gt; 35 screen ) 12 . Inability perform 6 Minute Walk Test ( 6MWT ) Pulmonary Function Test ( PFT ) maneuver 13 . Sickle cell disease ( Hemoglobin SS , Hemoglobin SC , sickle cellbeta thalassemia ) 14 . Treatment time B cell deplete therapy 15 . Any biologic antitumor necrosis factor ( antiTNF ) therapy within previous year 16 . Active infection require treatment within 30 day prior screen 17 . Pregnant lactating female 18 . Aspartate transaminase ( AST ) , alanine aminotransferase ( ALT ) creatine phosphokinase ( CPK ) &gt; 2 x upper limit normal screen 19 . Active infection hepatitis B hepatitis C 20 . Known infection human immunodeficiency virus ( HIV ) 21 . Creatinine level &gt; 1.5 time upper limit normal 22 . Platelet count &lt; 100,000/µL ( &lt; 100 x 109/L ) 23 . White blood cell count &lt; 3,000/cu mm ( &lt; 3.0 x 109/L ) &gt; 20,000/cu mm ( &gt; 20 x 109/L ) 24 . Organic heart disease ( e.g. , congestive heart failure , cor pulmonale ) , myocardial infarction within six month prior screen 25 . Clinically significant finding electrocardiogram ( ECG ) screening ( eg , arrhythmia ) 26 . History malignancy within 5 year ( except basal cell carcinoma skin surgically cure , remote history cancer consider cure positive Pap smear subsequent negative followup ) 27 . Documented prior history neurological disease evidence ongoing neurological disease 28 . Known allergy bovine porcine product 29 . Subject receive investigational agent ( agent device approve Federal Drug Administration ( FDA ) market use indication ) within 90 day ( 5 halflives , whichever long ) prior treatment investigational product ( IP ) 30 . Subject receive previous cell therapy 31 . Subject expect elective surgery within 12 week prior post dose IP surgery would expect confound evaluation outcome endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Sarcoidosis</keyword>
	<keyword>Stem cell</keyword>
	<keyword>PDA001</keyword>
	<keyword>Celgene</keyword>
	<keyword>Human Placenta-Derived cell</keyword>
	<keyword>Cenplacel-L</keyword>
</DOC>